Durable Complete Remissions Achieved in NHL Following CAR TDecember 8th 2019
Complete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.
New Approaches Target Overcoming Resistance to TKIs in EGFR+ NSCLCJune 2nd 2019
The treatment of <em>EGFR</em>-mutant non–small cell lung cancer has experienced significant improvements with the development of tyrosine kinase inhibitors, but resistance mechanisms that promote disease recurrence have tampered the runaway success of these revolutionary agents, said Katerina A. Politi, PhD, during the 2019 ASCO Annual Meeting. Early findings are presented for 2 novel agents aiming to potentially overcome resistance.
Novel Immune Checkpoint Identified as Promising Target for Blockade StrategiesNovember 12th 2016
A new immune checkpoint called PVRIG has emerged as a ripe target for anticancer therapy in solid tumors and an antibody that blocks its ability to suppress an antitumor response is in development.<br />